Joël Shapiro

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

Joël Shapiro, J. Jan B. van Lanschot, Maarten C.C.M. Hulshof et al. · The Lancet Oncology · 2015 · 2.5K citations

Surgical Oncology, Neoadjuvant Chemoradiotherapy, Esophageal Cancer +9

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

Ben M. Eyck, J. Jan B. van Lanschot, Maarten C.C.M. Hulshof et al. · Journal of Clinical Oncology · 2021 · 709 citations · Full text

Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study

Bo Jan Noordman, Manon C.W. Spaander, Roelf Valkema et al. · The Lancet Oncology · 2018 · 320 citations

Residual Disease, Surgical Oncology, Esophageal Cancer +11

Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A

Mary J. Pulvino, Yuejin Liang, David Oleksyn et al. · Blood · 2012 · 163 citations · Full text

Lymph Node Retrieval During Esophagectomy With and Without Neoadjuvant Chemoradiotherapy

Aaldert K. Talsma, Joël Shapiro, Caspar W. N. Looman et al. · Annals of Surgery · 2014 · 157 citations